Frontiers in Clinical Drug Research - Anti-Allergy Agents : (Record no. 4410)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 08468nam a22004813i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC5491306 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240724113318.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2018 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781681083377 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781681083384 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC5491306 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL5491306 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1048922805 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC48 .F766 2018 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Atta-ur-Rahman. |
| 245 10 - TITLE STATEMENT | |
| Title | Frontiers in Clinical Drug Research - Anti-Allergy Agents : |
| Remainder of title | Volume 3. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Sharjah : |
| Name of producer, publisher, distributor, manufacturer | Bentham Science Publishers, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2018. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2018. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (257 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 490 1# - SERIES STATEMENT | |
| Series statement | Frontiers in Clinical Drug Research - Anti-Allergy Agents Series ; |
| Volume/sequential designation | v.3 |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro -- CONTENTS -- PREFACE -- List of Contributors -- Developing the Perfect Antihistamine for Use in Allergic Conditions: A Voyage in H1 Selectivity -- Diana R. Cundell* and Kathryn E. Mickle -- INTRODUCTION -- Pharmacology of Histamine -- Cellular Sources of Histamine and Mechanisms of Release -- Mast Cells and the Inflammatory Environment -- Histamine and Body Tissues -- Antihistamines for the Treatment of Allergies -- Nasal Anatomy and Physiology, Allergic Rhinitis, Allergens and Histamine -- Allergens and Allergic Rhinitis -- The Eye Conjunctiva -- Anatomy And Physiology, Allergic Conjunctivitis and Histamine -- Allergens and Allergic Conjunctivitis -- The Skin -- Anatomy and Physiology, Urticaria and Histamine -- Allergens and Urticaria -- Histamine and the H1 Receptor -- First Generation H1 Antihistamines -- A History of First Generation Antihistamine Development -- Ethylenediamines and Ethanolamines -- Piperazines and Piperidines -- Phenothiazines and Doxepin -- A New Genre of Antihistamines With Powerful Central Nervous System Effects -- Side Effects of The First Generation H1 Antihistamines and Toxicity -- Central Nervous System H1 Side Effects -- Adverse Effects of First Generation H1 Antihistamines Due to Lack of Selectivity -- Toxicity of First Generation Antihistamines -- Second Generation H1 Antihistamines -- Safer with Less Side Effects -- Second Generation Antihistamines With Significant Side Effects: Astemizole, Azelastine and Terfenadine -- Second Generation Histamines That are First Generation Analogs -- Acrivastine, Cetirizine and Levocetirizine -- Cetirizine -- Levocetirizine -- Second Generation Piperidine Successes -- Levocabastine, Loratadine, Desloratadine, Fexofenadine, and Olopatadine -- Loratadine -- Desloratadine -- Fexofenadine -- Olopatadine. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Clinical Trial Meta-Analysis Data for Extensively Used Second Generation Antihistamines -- CONCLUSION AND FURTHER DIRECTIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Therapeutics in Chronic Spontaneous Urticaria -- Alexei Gonzalez-Estrada* and James Fernandez -- INTRODUCTION -- TREATMENT -- ANTIHISTAMINES -- H1-Antihistamines -- FIRST-GENERATION H1-ANTIHISTAMINES -- Hydroxyzine -- Doxepin -- SECOND-GENERATION H1-ANTIHISTAMINES -- Cetirizine -- Desloratadine -- Loratadine -- Fexofenadine -- Levocetirizine -- Rupatadine -- H2-Antihistamines -- Cimetidine -- Ranitidine -- Famotidine -- Leukotriene Antagonist -- Montelukast -- Zafirlukast -- IMMUNOSUPPRESSIVE MEDICATIONS FOR CSU -- Hydroxychloroquine -- Colchicine -- Dapsone -- Sulfasalazine -- Methotrexate -- Cyclosporine -- IMMUNOMODULATORY AGENTS -- Omalizumab -- Intravenous Immunoglobulin -- Corticosteroids -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Research and Development for Anti-Asthmatic Agents with a Focus on Phenotype Changing by Ca2+ Signaling in Airway Smooth Muscle Cells -- Hiroaki Kume1,2,* -- INTRODUCTION -- MECHANISM OF AIRWAY SMOOTH MUSCLE TONE -- AIRWAY SMOOTH MUSCLE TONE REGULATED BY KCA CHANNELS -- Characteristics and physiological roles of KCa channels -- Structure of KCa Channels -- Electrical Characteristics of KCa Channels -- Physiological Role of KCa Channels -- Stimulatory Regulation of KCa Channels by β2-Adrenoceptor Agonists -- cAMP-Dependent Phosphorylation -- Membrane-Delimited Activation by Gs -- Dual Regulation by cAMP-Dependent and -Independent Processes -- Role in Relaxation by β2-Adrenoceptor Agonists -- Inhibitory Regulation of KCa Channels by Muscarinic Receptor Agonists -- Membrane-Delimited Inhibition by Gi -- Dual Regulation by Gs and Gi. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Role in Contraction by Muscarinic Receptor Agonists -- Regulation of KCa Channels by other Factors (cGMP, Protein Kinase C) -- AIRWAY SMOOTH MUSCLE TONE REGULATED BY CA2+ DYNAMICS -- Membrane Potential-Independent Ca2+ Dynamics -- Membrane Potential-dependent Ca2+ Dynamics -- Effects of Ca2+ Release from the SR -- AIRWAY SMOOTH MUSCLE TONE REGULATED BY CA2+ SENSITIZATION -- Characteristics and Physiological Role of RhoA / Rho-kinase -- Role of RhoA / Rho-kinase on Contraction -- Role on β2-Adrenergic Relaxation -- INTRINSIC EFFICACY OF Β2-ADRENOCEPTOR AGONISTS -- Characteristics and Measurement -- Values of β2-Adrenergic Intrinsic Efficacy for Airway Smooth Muscle Relaxation -- Effects of Intrinsic Efficacy on β2-Adrenegic Desensitization -- Role of Allosteric GPCR Modulation in Intrinsic Efficacy -- ROLE OF CA2+ SIGNALING IN AIRWAY DISORDERS -- Airflow Limitation (Bronchoconstriction) -- Airway Hyperresponsiveness -- Desensitization of β2- Adrenoceptors -- Ca2+ Dynamics -- Ca2+ Sensitization -- Airway Remodeling -- Cell Proliferation -- Cell Migration -- Interaction between Airway Smooth Muscle and Inflammatory Cells -- PHENOTYPE PLASTICITY -- Contractile phenotype -- Synthetic and Proliferative Phenotypes -- Hyper-Contractile Phenotype -- Ca2+ Handling -- Regulation of Phenotype Switching -- Modulation of Cell Phenotype by Cell Culture -- RATIONALE USE OF Β2-ADRENOCEPTOR AGONISTS BASED ON THEIR INTRINSIC EFFICACY -- SYNERGISTIC EFFECTS BETWEEN MUSCARINIC AND Β2-ADRENERGIC RECEPTORS -- Role of G proteins / KCa Channels Linkage -- Role of Allosteric GPCR Modulation in Synergistic Effects -- POSSIBLE EFFECTS OF BRONCHODILATORS ON AIRWAY INFLAMMATION -- CONCLUSIONS -- ABBREVIATION -- CONSENT FOR PUBLICATION -- ACKNOWLEDGEMENT -- CONFLICT OF INTEREST STATEMENT -- REFERENCES -- Effects of Allergic Rhinitis on Communication Skills. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Can Cemal Cingi1,*, Erkan Yüksel2 and Nuray Bayar Muluk3 -- 1. INTRODUCTION -- 2. EFFECTS OF ALLERGIC RHINITIS ON HUMAN RELATIONS -- 2.1. Psychological Effects -- 2.2. Physiological Effects -- 2.3. Behavioral Effects -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Endosomal Toll-like Receptors: Rheostats of Inflammation and Diseases -- Chhedi Lal Gupta, Rohit Kumar Tiwari, Neelam Pathak and Preeti Bajpai* -- AN OVERVIEW -- Toll-like Receptors -- Structure of Toll-like Receptors -- Toll-like Receptor Signaling -- ENDOSOMAL TOLL-LIKE RECEPTORS -- Ligand Detection by Endosomal TLRs -- dsRNA Detection by TLR3 -- ssRNA Detection by TLR7 and TLR8 -- CpG DNA Detection by TLR9 -- Endosomal TLRs in Disease Aggravation -- Role of Endosomal TLRs in Inflammatory and Autoimmune Diseases -- Role of Endosomal TLRs in Cancer -- Therapeutic Targeting of Endosomal TLRs -- Agonists of Endosomal TLRs -- Antagonists of Endosomal TLRs -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- SUBJECT INDEX. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Clinical medicine. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Medical innovations. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Atta-ur-Rahman |
| Title | Frontiers in Clinical Drug Research - Anti-Allergy Agents: Volume 3 |
| Place, publisher, and date of publication | Sharjah : Bentham Science Publishers,c2018 |
| International Standard Book Number | 9781681083384 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | Frontiers in Clinical Drug Research - Anti-Allergy Agents Series |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5491306">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5491306</a> |
| Public note | Click to View |
No items available.